Targeting the calmodulin-regulated ErbB/Grb7 signaling axis in cancer therapy

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 2, 2013, Pages 177-189

  Villalobo, Antonio ^a   García Palmero, Irene ^a   Stateva, Silviya R ^a   Jellali, Karim ^b  

^a CSIC   (Spain)

^b CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALMODULIN; CALMODULIN INHIBITOR; CYSTEINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 INHIBITOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; THREONINE; TRASTUZUMAB; TRYPTOPHYLPHENYLALANYLGLUTAMYLGLYCYLTYROSYLASPARTYLASPARAGINYLTHREONYLPHENYLALANYLPROLYLCYSTEINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CELL PROLIFERATION; DIMERIZATION; DNA REPAIR; DRUG POTENTIATION; ENZYME REGULATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; INTERNALIZATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PERITONEUM METASTASIS; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 84889880020     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3V59V     Document Type: Article

References (136)

1. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature, 1984; 311:483-485.
2. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem, 1987; 56:881-914.
3. Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A, Schlessinger J. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails: identification of a novel site in EGF receptor. J Biol Chem, 1989; 264:10667-10671.
4. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res, 2003; 284:31-53.
5. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett, 1997; 410:83-86.
6. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res, 2003; 284:2-13.
7. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 2006; 125:1137-1149.
8. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res, 2003; 284:54-65.
9. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 2006; 7:505-515.
10. Warren CM, Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal, 2006; 18:923-933.
11. Alwan HAJ, van Zoelen EJJ, van Leeuwen JEM. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem, 2003; 278:35781-35790.
12. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res, 2003; 284:78-88.
13. Kirisits A, Pils D, Krainer M. Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int J Biochem Cell Biol, 2007; 39:2173-2182.
14. Cohen BD, Siegall CB, Bacus S, Foy L, Green JM, Hellström I, Hellström KE, Fell HP. Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma. Biochem Soc Symp, 1998; 63:199-210.
15. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol, 2006; 16:649-656.
16. Reinehr R, Häussinger D. Epidermal growth factor receptor signaling in liver cell proliferation and apoptosis. Biol Chem, 2009; 390:1033-1037.
17. Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res, 2009; 315:707-716.
18. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opi Cell Biol, 2009; 21:177-184.
19. Rush JS, Quinalty LM, Engelman L, Sherry DM, Ceresa BP. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem, 2012; 287:712-722.
20. Margolis B. The GRB family of SH2 domain proteins. Prog Biophys Mol Biol, 1994; 62:223-244.
21. Daly RJ. The Grb7 family of signalling proteins. Cell Signal, 1998; 10:613-618.
22. Han DC, Shen T-L, Guan J-L. The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions. Oncogene, 2001; 20:6315-6321.
23. Villalobo A, Li H, Sánchez-Torres J. The Grb7 protein family. Curr Top Biochem Res, 2003; 5:105-114.
24. Lucas-Fernández E, García-Palmero I, Villalobo A. Genomic organization and control of the Grb7 gene family. Curr Genomics, 2008; 9:60-68.
25. Manser J, Wood WB. Mutations affecting embryonic cell migrations in Caenorhabditis elegans. Dev Genet, 1990; 11:49-64.
26. Manser J, Roonprapunt C, Margolis B. C. elegans cell migration gene mig-10 shares similarities with a family of SH2 domain proteins and acts cell nonautonomously in excretory canal development. Dev Biol, 1997; 184:150-164.
27. Han DC, Guan J-L. Association of focal adhesion kinase with Grb7 and its role in cell migration. J Biol Chem, 1999; 274:24425-24430.
28. Han DC, Shen T-L, Miao H, Wang B, Guan J-L. EphB1 associates with Grb7 and regulates cell migration. J Biol Chem, 2002; 277:45655-45661.
29. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K. A novel variant of human Grb7 is associated with invasive esophaheal carcinoma. J Clin Invest, 1998; 102:821-827.
30. Tanaka S, Sugimachi K, Kawaguchi H, Saeki H, Ohno S, Wands JR, Sugimachi K. Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma. J Cell Physiol, 2000; 183:411-415.
31. Wang Y, Chan DW, Liu VWS, Chu PM, Ngan HYS. Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis. Clin Cancer Res, 2010; 16:2529-2539.
32. Ramsey B, Bai T, Newell AH, Troxell M, Park B, Olson S, Keenan E, Luoh S-W. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat, 2011; 127:659-669.
33. Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA, Kenny PA. GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res Treat, 2012; 133:607-615.
34. Chu P-Y, Huang L-Y, Hsu C-H, Liang C-C, Guan J-L, Hung T-H, Shen T-L. Tyrosine phosphorylation of growth factor receptor-bound protein-7 by focal adhesion kinase in the regulation of cell migration, proliferation, and tumorigenesis. J Biol Chem, 2009; 284:20215-20226.
35. Chu P-Y, Li T-K, Ding S-T, Lai I-R, Shen T-L. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. J Biol Chem, 2010; 285:29279-29285.
36. Kao J, Pollack J-R. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chrom Cancer, 2006; 45:761-769.
37. Pero SC, Shukla GS, Cookson MM, Flemer S Jr, Krag DN. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br J Cancer, 2007; 96:1520-1525.
38. García-Palmero I, López-Larrubia P, Cerdán S, Villalobo A. Nuclear magnetic resonance imaging of tumour growth and neovasculature performance in vivo reveals Grb7 as a novel antiangiogenic target. NMR Biomed, 2013; doi: 10.1002/nbm.2918.
39. Tsai N-P, Bi J, Wei L-N. The adaptor Grb7 links netrin-1 signaling to regulation of mRNA translation. EMBO J, 2007; 26:1522-1531.
40. Tsai N-P, Ho P-C, Wei L-N. Regulation of stress granule dynamics by Grb7 and FAK signaling pathway. EMBO J, 2008; 27:715-726.
41. Li H, Sánchez-Torres J, del Carpio AF, Nogales-González A, Molina-Ortiz P, Moreno MJ, Török K, Villalobo A. The adaptor Grb7 is a new calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7. Oncogene, 2005; 24:4206-4219.
42. Klee CB, Crouch TH, Richman PG. Calmodulin. Ann Rev Biochem, 1980; 49:489-515.
43. Chin D, Means AR. Calmodulin: a prototypical calcium sensor. Trends Cell Biol, 2000; 10:322-328.
44. 2+- calmodulin in intact cells. J Biol Chem, 1999; 274:6827-6830.
45. Dagher R, Peng S, Gioria S, Fève M, Zeniou M, Zimmermann M, Pigault C, Haiech J, Kilhoffer M-C. A general strategy to characterize calmodulin-calcium complexes in CaM-target recognition: DAPK and EGFR calmodulin binding domains interact with different calmodulin-calcium complexes. Biochim Biophys Acta, 2011; 1813:1059-1067.
46. 2+/calmodulin-dependent protein kinase II (CaMKII) is activated by calmodulin with two bound calciums. Proc Natl Acad Sci USA, 2006; 103:13968-13973.
47. Jurado LA, Chockalingam PS, Jarrett HW. Apocalmodulin. Physiol Rev, 1999; 79:661-682.
48. O'Neil KT, DeGrado WF. How calmodulin binds its targets: sequence independent recognition of amphiphilic α-helices. Trends Biochem Sci, 1990; 15:59-64.
49. Rhoads AR, Friedberg F. Sequence motifs for calmodulin recognition. FASEB J, 1997; 11:331-340.
50. Hoeflich KP, Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell, 2002; 108:739-742.
51. Wei JW, Hickie RZ, Klaassen DJ. Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. Cancer Chemother Pharmacol, 1983; 11:86-90.
52. Hait WN, Lazo JS. Calmodulin: a potential target for cancer chemotherapeutic agents. J Clin Oncol, 1986; 4:994-1012.
53. Orosz F, Horváth I, Ovádi J. New anti-mitotic drugs with distinct anti-calmodulin activity. Mini Rev Med Chem, 2006; 6:1145-1157.
54. Mayur YC, Jagadeesh S, Thimmaiah KN. Targeting calmodulin in reversing multi drug resistance in cancer cells. Mini Rev Med Chem, 2006; 6:1383-1389.
55. Weiss B, Prozialeck WC, Wallace TL. Interaction of drugs with calmodulin: biochemical, pharmacological and clinical implications. Biochem Pharmacol, 1982; 31:2217-2226.
56. Roufogalis BD, Minocherhomjee AM, Al-Jobore A. Pharmacological antagonism of calmodulin. Can J Biochem Cell Biol, 1983; 61:927-933.
57. Walsh MP. Calmodulin: structure-function relations and inhibitors. Rev Clin Basic Pharm, 1985; 5:35-69.
58. Veigl ML, Klevit RE, Sedwick WD. The use and limitations of calmodulin antagonists. Pharmacol Ther, 1989; 44:181-239.
59. Hidaka H, Ishikawa T. Molecular pharmacology of calmodulin pathways in the cell functions. Cell Calcium, 1992; 13:465-472.
60. Martínez-Luis S, Pérez-Vásquez A, Mata R. Natural products with calmodulin inhibitor properties. Phytochemistry, 2007; 68:1882-1903.
61. Takuwa N, Zhow W, Takuwa Y. Calcium, calmodulin and cell cycle progression. Cell Signal, 1995; 7:93-104.
62. Sánchez-González P, Jellali K, Villalobo A. Calmodulin-mediated regulation of the epidermal growth factor receptor. FEBS J, 2010; 277:327-342.
63. San José E, Benguría A, Geller P, Villalobo A. Calmodulin inhibits the epidermal growth factor receptor tyrosine kinase. J Biol Chem, 1992; 267:15237-15245.
64. Martín-Nieto J, Villalobo A. The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. Biochemistry, 1998; 37:227-236.
65. Aifa S, Johansen K, Nilsson UK, Liedberg B, Lundström I, Svensson SPS. Interactions between the juxtamembrane domain of the EGFR and calmodulin measured by surface plasmon resonance. Cell Signal, 2002; 14:1005-1013.
66. Li H, Villalobo A. Evidence for the direct interaction between calmodulin and the human epidermal growth factor receptor. Biochem J, 2002; 362:499-505.
67. Li H, Ruano MJ, Villalobo A. Endogenous calmodulin interacts with the epidermal growth factor receptor in living cells. FEBS Lett, 2004; 559:175-180.
68. McLaughlin S, Smith SO, Hayman MJ, Murray D. An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. J Gen Physiol, 2005; 126:41-53.
69. Aifa S, Aydin J, Nordvall G, Lundström I, Svensson SPS, Hermanson O. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. Exp Cell Res, 2005; 302:108-114.
70. 2+/calmodulin. Biochemistry, 2006; 45:12704-12714.
71. Sengupta P, Ruano MJ, Tebar F, Golebiewska U, Zaitseva I, Enrich C, McLaughlin S, Villalobo A. Membrane-permeable calmodulin inhibitors (e.g., W-7/W-13) bind to membranes, changing the electrostatic surface potential: dual effect of W-13 on EGFR activation. J Biol Chem, 2007; 282:8474-8486.
72. Panina S, Stephan A, La Cour JM, Jacobsen K, Kallerup LK, Bumbuleviciute R, Knudsen KVK, Sánchez-González P, Villalobo A, Olesen UH, Berchtold MW. Significance of calcium binding, tyrosine phosphorylation, and lysine trimethylation for the essential function of calmodulin in vertebrate cells analyzed in a novel gene replacement system. J Biol Chem, 2012; 287:18173-18181.
73. Li H, Panina S, Kaur A, Ruano MJ, Sánchez-González P, La Cour JM, Stephan A, Olesen UH, Berchtold MW, Villalobo A. Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin. J Biol Chem, 2012; 287:3273-3281.
74. Martín-Nieto J, Cusidó-Hita DM, Li H, Benguría A, Villalobo A, Regulation of ErbB receptors by calmodulin, in Pandalai SG (ed), Recent Research Developments in Biochemistry vol. 3, Research Signpost, Trivandrum, pp. 41-58, 2002.
75. Li H, Sánchez-Torres J, del Carpio A, Salas V, Villalobo A. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein. Biochem J, 2004; 381:257-266.
76. White CD, Li Z, Sacks DB. Calmodulin binds HER2 and modulates HER2 signaling. Biochim Biophys Acta, 2011; 1813:1074-1082.
77. Villalobo A, García-Andrés C, Molina-Ortiz P. Translocation of ErbB receptors into the nucleus. Rev Oncol, 2003; 5:381-389.
78. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med, 2011; 12:419-432.
79. Wang Y-N, Hung M-C. Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci, 2012; 2:13.
80. Lin S-Y, Makino K, Xia WY, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol, 2001; 3:802-808.
81. Schlessinger J, Lemmon MA. Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell, 2006; 127:45-48.
82. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res, 1999; 253:78-87.
83. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene, 2000; 19:6115-6121.
84. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation: biological significance and potential target for anti-cancer therapy. Ann Oncol, 2001; 12:745-760.
85. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun, 2004; 319:1-11.
86. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature, 2004; 431:525-526.
87. Arjona D, Bello MJ, Alonso ME, González-Gómez P, Aminoso C, Isla A, de Campos JM, Vaquero J, Gutierrez M, Villalobo A, Rey JA. Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol, 2005; 31:384-394.
88. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007; 7:169-181.
89. Gan HK, Kave AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci, 2009; 16:748-754.
90. Pines G, Köstler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett, 2010; 584:2699-2706.
91. Da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol, 2011; 6:49-69.
92. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res, 2012; 18:4910-4918.
93. Grossmann AH, Samowitz WS. Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. Arch Pathol Lab Med, 2011; 135:1278-1282.
94. Anderson NG, Ahmad T. ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Front Biosci, 2002; 7:d1926-d1940.
95. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol, 2002; 194:13-19.
96. Normanno N, Maiello MR, Mancino M, De Luca A. Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. J Chemother, 2004; 16 Suppl 4:36-40.
97. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer, 2004; 90:2250-2255.
98. Mendelson J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol, 2006; 33:369-385.
99. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist, 2007; 12:325-330.
100. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res, 2012; 18:938-944.
101. Sawatdichaikul O, Hannongbua S, Sangma C, Wolschann P, Choowongkomon K. In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database. J Mol Model, 2012; 18:1241-1254.
102. Lipton A, Villalobo A. EGFR-targeted cancer research: continuing progress and changing views (Editorial). Signal, 2001; 2:2-3.
103. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol, 2005; 23:2445-2459.
104. De Lorenzo C, D'Alessio G. Human anti-ErbB2 immunoagents - immunoRNases and compact antibodies. FEBS J, 2009; 276:1527-1535.
105. Markman B, Capdevilla J, Elez E, Tabernero J. New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy, 2009; 1:965-982.
106. Elloumi J, Jellali K, Jemel I, Aifa S. Monoclonal antibodies as cancer therapeutics. Rec Pat Biotechnol, 2012; 6:45-56.
107. Omidfar K, Shirvani Z. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. DNA Cell Biol, 2012; 1015-1026.
108. King CR, Kasprzyk PG, Fischer PH, Bird RE, Turner NA. Preclinical testing of an anti-erbB-2 recombinant toxin. Breast Cancer Res Treat, 1996; 38:19-25.
109. Altintas I, Kok RJ, Schiffelers RM. Targeting epidermal growth factor receptor in tumors: from conventional antibodies via heavy chain-only antibodies to nanobodies. Eur J Pharm Sci, 2012; 45:399-407.
110. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res, 2007; 13:378-381.
111. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res, 2008; 14:2895-2899.
112. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci, 2011; 102:1-8.
113. Ayoola A, Barochia A, Belani K, Belani CP. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest, 2012; 30:433-446.
114. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol, 2001; 28:18-26.
115. Chaudhary P, Gaira A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc Hematol Agents Med Chem, 2010; 8:156-163.
116. Yamane K, Toyoshima C, Nishimura S. Ligand-induced functions of the epidermal growth factor receptor require the positively charged region asymmetrically distributed across plasma membrane. Biochem Biophys Res Commun, 1992; 184:1301-1310.
117. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell, 2009; 34:641-651.
118. He L, Hristova K. Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence. Sci Rep, 2012; 2:854.
119. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell, 2009; 137:1293-1307.
120. Park SW, Chung NG, Han JY, Eom HS, Yoo NJ, Lee SH. Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers. Acta Pathol Microbiol Immunol Scand, 2009; 118:83-84.
121. Arjona D, Bello MJ, Alonso ME, González-Gómez P, Lomas J, Aminoso C, López-Marín I, Isla A, de Campos JM, Vaquero J, Villalobo A, Rey JA. Molecular analysis of the erbB gene family calmodulin-binding domain and calmodulin-like domain in astrocytic gliomas. Int J Oncol, 2004; 25:1489-1494.
122. Boran ADW, Seco J, Jayaraman V, Jayaraman G, Zhao S, Reddy S, Chen Y, Iyengar R. A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor. PLoS One, 2012; 7:e49702.
123. Ward NE, Gravitt KR, O'Brian CA. Irreversible inactivation of protein kinase C by a peptide-substrate analog. J Biol Chem, 1995; 270:8056-8060.
124. Hunter T, Ling N, Cooper JA. (1984) Protein kinase C phosphorylation of the EGF receptor at threonine residue close to the cytoplasmic face of the plasma membrane. Nature, 1984; 311:480-483.
125. von Heijne G. The signal peptide. J Membr Biol, 1990; 115:195-201
126. Lin Y-Z, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem, 1995; 270:14255-14258.
127. Rojas M, Yao SY, Lin Y-Z. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem, 1996; 271:27456-27461.
128. Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem, 2007; 282:10432-10440.
129. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation. Cancer Res, 2011; 71:1103-1114.
130. García-Palmero I, Villalobo A. Calmodulin regulates the translocation of Grb7 into the nucleus. FEBS Lett, 2012; 586:1533-1539.
131. Chan DW, Hui WW, Cai PC, Liu MX, Yung MM, Mak CS, Leung TH, Chan KK, Ngan HY. Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. PLoS One, 2012; 7:e52578.
132. Pero SC, Daly RJ, Krag DN. Grb7-based molecular therapeutics in cancer. Expert Rev Mol Med, 2003; 5:1-11.
133. Pero SC, Oligino L, Daly RJ, Soden AL, Liu C, Roller PP, Li P, Krag DN. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J Biol Chem, 2002; 277:11918-11926.
134. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst, 2006; 98:491-498.
135. Ambaye ND, Gunzburg MJ, Lim RCC, Price JT, Wilce MCJ, Wilce JA. Benzopyrazine derivatives: a novel class of growth factor receptor bound protein 7 antagonists. Bioorg Med Chem, 2011; 19:693-701.
136. Ambaye ND, Gunzburg MJ, Lim RCC, Price JT, Wilce MCJ, Wilce JA. The discovery of phenylbenzamide derivatives as grb7-based antitumor agents. ChemMedChem, 2013; 8:280-288.